Applied Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In New York Citydedicated To Developing Innovative Therapies For Rare Diseases And Conditions With Significant Unmet Medical Needsfounded In 2016The Company Employs Around 35 People And Is Publicly Traded Under The Ticker Apltthe Company Specializes In Aldose Reductase Inhibitorsarisand Has A Robust Pipeline Targeting Rare Metabolic And Diabetic Complicationsits Lead Productgovorestatat 007 Is In Phase 3 Trials For Galactosemia And Is Also Being Developed For Sord Deficiency And Pmm2 Cdgadditionallyat 001 Is In Phase 3 For Diabetic Cardiomyopathywhile At 003 Is In Preclinical Development For Diabetic Retinopathyapplied Therapeutics Emphasizes Biomarker Driven Development To Enhance The Efficiency Of Clinical Trials And Has Partnered With Mercury Pharma Group For The Commercialization Of At 007The Company Aims To Create Effective Treatments For Patients Facing Limited Options In Rare Diseases
